Redx make senior management appointments

Redx is pleased to announce two senior management appointments, with Nicholas Adams joining as Chief Business Officer and Dr Matilda Bingham’s promotion to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.

Nicholas Adams’s role as Chief Business Officer is a newly developed position and his appointment commences on 19 November. Nick has over 25 years’ experience in the pharmaceutical industry, and in particular in business development. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.

Dr Matilda (“Tilly”) Bingham has been appointed as Executive Director of Redx Oncology Ltd, with immediate effect, having served as Interim Managing Director of the subsidiary. She joined Redx in 2012 from MSD Research Laboratories, part of Merck & Co., Inc., where she led the medicinal chemistry teams. She has over 13 years of experience in the pharmaceutical industry, with a track record of delivering clinical development candidates.

Neil Murray, Chief Executive of Redx, commented:

“We are delighted to announce the appointments of Nick and Tilly to our executive management team. Nick brings extensive experience in business development roles as well as a strong clinical background. I am equally pleased that Tilly has been promoted to the position of Executive Director of Redx Oncology. She has been a valued member of the team since 2012, with a track record of delivery across the organisation.

These appointments are part of Redx’s growth strategy and will help to accelerate the Group’s next phase of development as a commercially driven drug discovery and development company.”

See for more details

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.